Terns Pharmaceuticals Inc at HC Wainwright Investment Conference - New York Transcript
Hi, good morning, everyone. Welcome to the H.C. Wainwright 25th Annual Global Investment Conference. For our next presentation, we have Terns Pharmaceuticals with CEO (sic - "CMO") here, Emil Kuriakose. Thank you very much for joining us today. Please go ahead.
Thank you. Hi, everyone. Thanks for your time. My name is Emil Kuriakose. I'm the CMO of Oncology at Terns Pharmaceuticals. I'll be making forward-looking statements today, so please visit our website for the relevant disclosures.
So just to provide a high-level investment highlight of our company, the theme of the company is, essentially, that we are developing small-molecule medicines that have clinically validated mechanisms of action. And we are in several disease areas, primarily oncology; metabolic diseases, namely NASH; and obesity, all of which have large unmet need. The key point here is that because these mechanisms and targets are clinically validated, it largely de-risks the clinical risk in terms of
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |